Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (4'-ethyl-2-methyl-3-piperidino)propiophenone
2. 4-empp
3. E-0646
4. Eperisone
1. 56839-43-1
2. Eperisone Hcl
3. Myonal
4. Mional
5. Empp
6. Eperisone, Hcl
7. E-646
8. 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Hydrochloride
9. Eperisone Hydrochloride [jan]
10. 4'-ethyl-2-methyl-3-piperidinopropiophenone Hydrochloride
11. U38o8u7p6x
12. 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-1-propanone Hydrochloride
13. 1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one;hydrochloride
14. Dsstox_cid_27822
15. Dsstox_rid_82585
16. Dsstox_gsid_47844
17. Cas-56839-43-1
18. Ncgc00167973-01
19. (4'-ethyl-2-methyl-3-piperidino)propiophenone
20. Unii-u38o8u7p6x
21. E 0646
22. Epenard (tn)
23. 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-, Hydrochloride
24. Eperisonehydrochloride
25. Dw-1030
26. Schembl218337
27. Chembl2360601
28. Dtxsid8047844
29. Eperisone Hydrochloride (jp17)
30. Chebi:31540
31. Bcp11969
32. Hy-b1901
33. Propiophenone, 4'-ethyl-2-methyl-3-piperidino-, Hydrochloride
34. Eperisone Hydrochloride [mi]
35. Tox21_112599
36. Mfcd00941459
37. Akos015843965
38. Tox21_112599_1
39. Ccg-267425
40. Eperisone Hydrochloride [mart.]
41. Ks-5241
42. Eperisone Hydrochloride [who-dd]
43. Ncgc00167973-02
44. Ac-15896
45. Db-052975
46. Cs-0013960
47. E2000
48. Ft-0602324
49. S4877
50. D01671
51. D95097
52. E-2000
53. A831198
54. Q27889924
55. 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-onehydrochloride
56. 1-(4-ethylphenyl)-2-methyl-3-(1-piperidyl)propan-1-one Hydrochloride;eperisone Hcl
| Molecular Weight | 295.8 g/mol |
|---|---|
| Molecular Formula | C17H26ClNO |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 295.1702921 g/mol |
| Monoisotopic Mass | 295.1702921 g/mol |
| Topological Polar Surface Area | 20.3 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 275 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.
Lead Product(s): Eperisone Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Myonal
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: DKSH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2022
Lead Product(s) : Eperisone Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : DKSH
Deal Size : Undisclosed
Deal Type : Agreement
Eisai To Divest Rights For Muscle Relaxant Myonal® And Vertigo And Equilibrium Disturbance Treatm...
Details : Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.
Product Name : Myonal
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 07, 2022
Details:
Pelubiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Back Pain.
Lead Product(s): Pelubiprofen,Eperisone Hydrochloride
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 07, 2018
Lead Product(s) : Pelubiprofen,Eperisone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pelubiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Back Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 07, 2018
Details:
Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Back Pain.
Lead Product(s): Eperisone Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2014
Lead Product(s) : Eperisone Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Back Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2014
Details:
Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Eperisone Hydrochloride,Diclofenac Sodium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2011
Lead Product(s) : Eperisone Hydrochloride,Diclofenac Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2011
Details:
Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Back Pain.
Lead Product(s): Eperisone Hydrochloride,Diclofenac Sodium
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2011
Lead Product(s) : Eperisone Hydrochloride,Diclofenac Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eperisone HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Back Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2011
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Annual Reports
Main Therapeutic Indication : Musculoskeletal
Currency : USD
2024 Revenue in Millions : 45
2023 Revenue in Millions : 71
Growth (%) : -36
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
88
PharmaCompass offers a list of Eperisone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Eperisone Hydrochloride manufacturer or Eperisone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eperisone Hydrochloride manufacturer or Eperisone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Eperisone Hydrochloride API Price utilized in the formulation of products. Eperisone Hydrochloride API Price is not always fixed or binding as the Eperisone Hydrochloride Price is obtained through a variety of data sources. The Eperisone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Myonal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Myonal, including repackagers and relabelers. The FDA regulates Myonal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Myonal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Myonal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Myonal supplier is an individual or a company that provides Myonal active pharmaceutical ingredient (API) or Myonal finished formulations upon request. The Myonal suppliers may include Myonal API manufacturers, exporters, distributors and traders.
click here to find a list of Myonal suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Myonal Drug Master File in Japan (Myonal JDMF) empowers Myonal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Myonal JDMF during the approval evaluation for pharmaceutical products. At the time of Myonal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Myonal suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Myonal Drug Master File in Korea (Myonal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Myonal. The MFDS reviews the Myonal KDMF as part of the drug registration process and uses the information provided in the Myonal KDMF to evaluate the safety and efficacy of the drug.
After submitting a Myonal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Myonal API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Myonal suppliers with KDMF on PharmaCompass.
A Myonal written confirmation (Myonal WC) is an official document issued by a regulatory agency to a Myonal manufacturer, verifying that the manufacturing facility of a Myonal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Myonal APIs or Myonal finished pharmaceutical products to another nation, regulatory agencies frequently require a Myonal WC (written confirmation) as part of the regulatory process.
click here to find a list of Myonal suppliers with Written Confirmation (WC) on PharmaCompass.
Myonal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Myonal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Myonal GMP manufacturer or Myonal GMP API supplier for your needs.
A Myonal CoA (Certificate of Analysis) is a formal document that attests to Myonal's compliance with Myonal specifications and serves as a tool for batch-level quality control.
Myonal CoA mostly includes findings from lab analyses of a specific batch. For each Myonal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Myonal may be tested according to a variety of international standards, such as European Pharmacopoeia (Myonal EP), Myonal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Myonal USP).
